Bicara Therapeutics BCAX Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost.
The official record: Bicara Therapeutics’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's effective income tax rate reconciliation nondeductible expense share based compensation cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's effective income tax rate reconciliation nondeductible expense share based compensation cost?
- Bicara Therapeutics (BCAX) reported effective income tax rate reconciliation nondeductible expense share based compensation cost of -0.5% in Q4 2025.
- What does effective income tax rate reconciliation nondeductible expense share based compensation cost mean?
- This metric captures the impact of non-deductible share-based compensation expenses on the effective tax rate reconciliation. It highlights the tax friction caused by equity-based awards that do not qualify for immediate tax deductions. Investors track this to understand the tax implications of the company's compensation strategy.